Objectives Radiochemotherapy is standard treatment for locally advanced cervical cancer. This study evaluates if concomitant RCHT and hyperthermia changes the treatment toxicity and efficacy.
Methods The analysis consisted of 50 women mean age 62,2 yrs (41–83) with cervical cancer (IIIB stage), treated with concurrent radiochemotherapy and intracavitary hyperthermia in GreatPoland Cancer Center in 2012–2013. Treatment contained radical 3D teletherapy 45–50 Gy (df 1,8Gy) and IGRT HDR brachytherapy 4x7Gy (GEC-ESTRO recommendation), weekly Cisplatin 40 mg/m2 and two-time hyperthermia. Hyperthermia, using one heating antenna and one thermometer inserted into applicators placed in the patient‘s cervical/uterus canal, was used. The BSD500 apparatus emiting radio waves (915MHz), was used for this operations. Elevated local temperature up to 41°C was maintained for one hour and the associated brachyradiotherapy fraction was realized within 1 hour after hyperthermia. The median number of chemotherapy cycles was 3,3 (0–6). The time of observation was min 63 months.
Results Toxicity according EORTC/RTOG scale was assessed: Early toxicity were not observed. The late toxicity from bladder I° and II° in 4 (8%) patients, IV° in 1 (2%)-fistula were noted. Toxicity from rectum I° and II° in 8 (16%) patients, IV° in 2 (4%) were sighted. Progression of disease in 5 of treated women were noted: 1 local relapse, 2 distant metastases and 2 patients with both way of recurrences.
Conclusions Concomitant radiochemotherapy and hyperthermia is an effective and safety treatment in women with IIIB stage cervical cancer. The number and causes of toxicity should and will be analyzed in the greater group of patients.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.